第53回〔日本結核病学会〕総会シンポジウム

概要

論文の詳細を見る
In Japan today, where long-term chemotherapy for pulmonary tuberculosis has been popu- larly routinized, the time is not yet ripe for accepting readily short-course chemotherapy whichis of British and French origin. As a matter of fact, long-term chemotherapy had severalshortcomings specific for its prolonged administration. Therefore, if short-course chemotherapyhas been proved not inferior to long-term chemotherapy in its therapeutic efficacy, the durationof chemotherapy for pulmonary tuberculosis should undoubtedly be shortened.<BR>In this symposium, therapeutic results of short-course chemotherapy for experimentaltuberculosis were presented by Drs. Kondo and Toyohara, while those of clinical studies werereported by 4 workers including Dr. Aizawa, all of which support and reconfirm the efficacyof short-course chemotherapy.<BR>The greatest anxiety manifested by the Japanese phthisiologists for the trial of short-coursechemotherapy has been nothing but the anxiety about the possibility of occurring relapse afterdiscontinuation of chemotherapy, -in particular, anxiety for the fate of remaining cavitiesand other unstable lesions, yet existing at the time of terminating the chemotherapy. Follow- up studies shall clarify these questions eventually. Drs. Aizawa, Kino, and Uragami showedon the basis of their respective data that the radiological improvements continued consistentlyafter the termination of chemotherapy.<BR>To ease their anxiety, reporters have elaborated their respective regimens, without stoppingchemotherapy indiscriminately within a fixed period but regulating the duration of treatment inaccordance with the rates of improvement in radiological findings and of bacteriological negative conversion.<BR>Nevertheless, attending physicians used to prolong the duration of chemotherapy in some20% of cases. This is the actual status of chemotherapy in Japan.
一般社団法人日本結核病学会の論文

著者

島村喜久治
国立療養所東京病院

第53回〔日本結核病学会〕総会シンポジウム

スポンサーリンク

概要

著者

関連論文

スポンサーリンク